B

BioAtla
D

BCAB

1.63500
USD
0.08
(4.81%)
مغلق
حجم التداول
10,789
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
79,045,012
الأخبار

العنوان: BioAtla

القطاع: Healthcare
الصناعة: Biotechnology
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.